Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hexokinase expansion in thermophilic snails supports extreme heat tolerance.

Science China. Life sciences·2026

Same author

A Combined Spectroscopic and Computational Study on the Electronic Structures of Cyclopentadienyl Bis-Phosphine Chromium(IV/V) Nitrides.

Inorganic chemistry·2026

Same author

A Missing Link in Dinitrogen Fixation Enabled by Hydrazido Isomerization.

Journal of the American Chemical Society·2026

Same author

Direct N-N Coupling between a Transient Iron(V)-Nitrido Complex and Nitrosobenzene Affording an Iron(III)-Phenyldiazene-<i>N</i>-Oxide.

Journal of the American Chemical Society·2026

Same author

Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease <i>via</i> peroxisome proliferator-activated receptor alpha pathway activation.

World journal of gastroenterology·2026

Same author

Trisilylation of a Formal Cr(-I) Bis-dinitrogen Complex.

Journal of the American Chemical Society·2025

Search research articles

Related Experiment Video

Updated: Jan 1, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

CAR T Cell Therapy for Hematological Malignancies.

Xin Yang¹, Gao-Xiang Wang¹, Jian-Feng Zhou²

¹Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Current Medical Science

|December 18, 2019

Summary

Chimeric antigen receptor (CAR) T cell therapy shows promise for blood cancers, particularly in relapsed/refractory cases. This review covers CAR T cell therapy

Keywords:

chimeric antigen receptor T cells hematological malignancies immune therapy

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Related Experiment Videos

Last Updated: Jan 1, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

Adoptive T cell transfer with chimeric antigen receptors (CARs) is a rapidly advancing oncology field.
CAR T cell therapy has demonstrated significant efficacy in treating hematological malignancies, with notable success in clinical trials.
This therapy shows exceptional potential for patients with relapsed or refractory cancers.

Purpose of the Study:

To summarize current knowledge on CAR T cell therapy.
To discuss receptor composition, applications, and adverse events.
To propose recommendations for future development.

Main Methods:

Review of existing literature and clinical trial data on CAR T cell therapy.
Analysis of CAR T cell receptor design and engineering principles.
Examination of safety profiles and toxicity management strategies.

Main Results:

CAR T cell therapy has achieved striking efficacy in hematological malignancies.
The therapy is particularly effective in relapsed/refractory patient populations.
Challenges include engineering, manufacturing, limited applications, and toxicities.

Conclusions:

CAR T cell therapy represents a powerful tool in oncology.
Addressing current challenges is crucial for broader application and improved patient outcomes.
Further research and strategic recommendations are needed to optimize this therapeutic approach.